EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The post-marketing safety of venlafaxine: a real-world two-decade pharmacovigilance study using the FAERS database

Santosh Chokkakula, Hualiang Yang, Abeer A Al-Masri, Yiquan Zhang, Bommireddy Naveen, Bing Yang

Frontiers in Pharmacology · 21.01.2026 · 17

DOI: 10.3389/fphar.2026.1737113 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 21.01.2026. Verfasst von Santosh Chokkakula und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Chungbuk National University College of Medicine and Medical Research Institute, Cheongju, Republic of Korea. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Venlafaxine, a serotonin-norepinephrine reuptake inhibitor widely prescribed for major depressive disorder and related conditions, remains insufficiently characterized regarding its adverse event profile. This study aimed to comprehensively evaluate the post-marketing safety of venlafaxine using data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).

Methods

The data were extracted from the FAERS database from the first quarter (Q1) 2004 to Q2 2025. Adverse drug events were analyzed using the Reporting Odds Ratio (ROR), Bayesian Confidence Propagation Neural Network (BCPNN), Proportional Reporting Ratio (PRR), and Multi-Item Gamma Poisson Shrinker (MGPS) methods.

Results

A total of 47,325 venlafaxine-related adverse event reports were analyzed. Disproportionality analysis revealed significant signals for drug ineffectiveness (n = 2,108, ROR = 1.6, PRR = 1.6, χ 2 = 483.4, IC = 0.7, EBGM = 1.6), drug hypersensitivity (n = 1,014; ROR = 4.9, PRR = 4.8, χ 2 = 2998.7, IC = 2.2, EBGM = 4.7), and anxiety (n = 198, ROR = 4.3, PRR = 4.2, χ 2 = 2202.0, IC = 2.0, EBGM = 4.1). Strongest signals (EBGM = 9.9) were observed for suicide attempt, agitated depression, and renal dysplasia. Tachycardia (EBGM = 8.3) was the most frequently reported adverse event among patients under 18 years, while emotional disorder (EBGM = 9.5) predominated in those aged 65 years and older. Most adverse events (39.3%) occurred within the first 30 days of venlafaxine therapy initiation.

Conclusion

This pharmacovigilance analysis systematically identified significant safety signals associated with venlafaxine. The findings provide important evidence to support safer clinical use of venlafaxine and may assist in optimizing individualized therapeutic decisions in practice.

Schlagwörter

Stichwörter der Autor:innen

FAERSdisproportionality analysismajor depressive disorderpharmacovigilancevenlafaxine

Autor:innen und Institutionen

  • Department of Microbiology, Chungbuk National University College of Medicine and Medical Research Institute, Cheongju, Republic of Korea.
  • Department of Pharmacy, Tianjin Central Hospital of Gynecology Obstetrics, Tianjin, China.
  • Department of Physiology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
  • School of Pharmacy, Tianjin Medical University, Tianjin, China.
  • Department of Chemical and Biological Engineering, Gachon University, Seongnam-Si, Gyeonggi-do, Republic of Korea.
  • Department of Cell Biology, College of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.

Zitieren

APA

Chokkakula, S., Yang, H., Al-Masri, A. A., Zhang, Y., Naveen, B., & Yang, B. (2026). The post-marketing safety of venlafaxine: a real-world two-decade pharmacovigilance study using the FAERS database. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1737113

Vancouver

Chokkakula S, Yang H, Al-Masri AA, Zhang Y, Naveen B, Yang B. The post-marketing safety of venlafaxine: a real-world two-decade pharmacovigilance study using the FAERS database. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1737113

BibTeX
@article{Chokkakula2026,
  author = {Chokkakula, Santosh and Yang, Hualiang and Al-Masri, Abeer A and Zhang, Yiquan and Naveen, Bommireddy and Yang, Bing},
  title = {The post-marketing safety of venlafaxine: a real-world two-decade pharmacovigilance study using the FAERS database},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1737113}
}
Kostenlos starten →